Endotoxin and thrombin elevate rodent endothelial cell protein C receptor mRNA levels and increase receptor shedding in vivo.
The endothelial cell protein C receptor (EPCR) facilitates protein C activation by the thrombin-thrombomodulin complex. Protein C activation has been shown to be critical to the host defense against septic shock. In cell culture, tumor necrosis factor-alpha (TNF-alpha) down-regulates EPCR expression, raising the possibility that EPCR might be down-regulated in septic shock. We examined EPCR mRNA and soluble EPCR levels in mice and rats challenged with lethal dose 95 levels of endotoxin. Toxic doses of TNF-alpha failed to alter EPCR mRNA levels in mice. Rather than EPCR mRNA levels falling in response to endotoxin, as predicted from cell-culture experiments, they rose approximately 3-fold 6 hours after exposure to endotoxin before returning toward baseline levels at 24 hours after exposure. Soluble EPCR levels rose approximately 4-fold. Infusion of hirudin, a specific thrombin inhibitor, before endotoxin exposure almost completely blocked the increase in EPCR mRNA and soluble EPCR. Consistent with the idea that the responses were mediated by thrombin, thrombin infusion (5 U/kg of body weight for 3 hours) resulted in an approximately 2-fold increase in EPCR mRNA and soluble EPCR. Incubation of rat endothelial cells with thrombin or murine protease-activated receptor 1 agonist peptide resulted in a 2-fold increase in EPCR mRNA. These results indicate that thrombin plays a major role in up-regulating EPCR mRNA and shedding in vivo. (Blood. 2000;95:1687-1693)
Gu
J M
JM
Cardiovascular Biology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma 73104, USA.
Katsuura
Y
Y
Ferrell
G L
GL
Grammas
P
P
Esmon
C T
CT
D000818:Animals; D000990:Antithrombin III / Q000378:metabolism; D001779:Blood Coagulation Factors; D016466:CHO Cells; D006224:Cricetinae; D003412:Cricetulus; D015536:Down-Regulation / Q000187:drug effects; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism; D019446:Endotoxemia / Q000235:genetics / Q000378:metabolism*; D004731:Endotoxins / Q000494:pharmacology*; D005340:Fibrinogen / Q000032:analysis; D005786:Gene Expression Regulation / Q000187:drug effects*; D006629:Hirudins / Q000494:pharmacology; D008168:Lung / Q000378:metabolism; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D009206:Myocardium / Q000378:metabolism; D009842:Oligopeptides / Q000494:pharmacology; D010447:Peptide Hydrolases / Q000378:metabolism; D011486:Protein C / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis*; D051381:Rats; D017207:Rats, Sprague-Dawley; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D011956:Receptors, Cell Surface / Q000096:biosynthesis* / Q000235:genetics; D018179:Receptors, Thrombin / Q000819:agonists; D013917:Thrombin / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000494:pharmacology; D015854:Up-Regulation / Q000187:drug effects
D001779:Blood Coagulation Factors; D004731:Endotoxins; D006629:Hirudins; D009842:Oligopeptides; D011486:Protein C; D012333:RNA, Messenger; D044463:Receptor, PAR-1; D044464:Receptor, PAR-2; D011956:Receptors, Cell Surface; D018179:Receptors, Thrombin; D014409:Tumor Necrosis Factor-alpha; C091963:activated protein C receptor; C046193:antithrombin III-protease complex; C099570:seryl-leucyl-isoleucyl-glycyl-arginyl-leucine; C405613:seryl-phenylalanyl-phenylalanyl--leucyl-arginyl-asparaginyl-prolyl-seryl-glutamic acid; D000990:Antithrombin III; D005340:Fibrinogen; D010447:Peptide Hydrolases; D013917:Thrombin